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candidiasis and candidemia are fre-
quently encountered in the
nosocomial setting, particularly in the
intensive care unit (ICU). Objectives
and methods: To review the current
management of invasive candidiasis
and candidemia in non-neutropenic
adult ICU patients based on a review
of the literature and a European
expert panel discussion. Results and
conclusions: Candida albicans
remains the most frequently isolated
fungal species followed by C. glab-
rata. The diagnosis of invasive
candidiasis involves both clinical and
laboratory parameters, but neither of
these are specific. One of the main
features in diagnosis is the evaluation
of risk factor for infection which will
identify patients in need of pre-emp-
tive or empiric treatment. Clinical
scores were built from those risk
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factors. Among laboratory diagnosis,
a positive blood culture from a nor-
mally sterile site provides positive
evidence. Surrogate markers have
also been proposed like 1,3 b-D glu-
can level, mannans, or PCR testing.
Invasive candidiasis and candidemia
is a growing concern in the ICU, apart
from cases with positive blood cul-
tures or fluid/tissue biopsy, diagnosis
is neither sensitive nor specific. The
diagnosis remains difficult and is
usually based on the evaluation of
risk factors.
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CAGT Candida albicans germ tube
CI Colonization index
DLY Discounted life year
FIO2 Fraction of inspired oxygen
HwP1 Hyphal wall protein 1
ICU Intensive care unit
INR International normalized
ratio
MAP Mean arterial blood pressure
OR Odds ratio
PaO2 Partial pressure of arterial
oxygen
PCR Polymerize chain reaction




SICU Surgical intensive care unit
SIRS Systemic inflammatory
response syndrome
SvO2 Mixed venous oxygen
saturation
WBC White blood cell
Introduction
Among documented invasive fungal infections, candide-
mia and invasive candidiasis are encountered with
increasing incidence in nosocomial settings [1]. These
infections cause considerable morbidity and mortality.
Several studies have estimated that 6–11% of all positive
nosocomial bloodstream infections could be attributed to
Candida spp. [1, 2]. However, a recent US study showed
that between 1991 and 2003, the mortality rate associated
with invasive candidiasis decreased slightly over time [2].
C. albicans has remained the main pathogen overall,
although the frequency of C. glabrata increases with age.
Data from a US surveillance study found that over a 7-
year period Candida spp. accounted for 4.6 bloodstream
infections per 10,000 admissions and 9% of all blood-
stream infections [1], whereas the incidence may vary
between centers. The estimated incidence of candidemia
also varies between countries In Europe, Denmark has
reported the highest incidence with 11.0 cases/100,000/
year compared with a study carried out in Finland which
only recorded 1.9 cases/100,000/year in the hospital
population [3–5]. Candida spp. are generally reported to
be the fourth-most prevalent pathogen isolated in blood
cultures or deep-site infections although this prevalence
varies depending on the population surveyed [1, 2]. In
intensive care units (ICUs), a slightly higher incidence is
usually observed; in one study carried out in the ICU
setting, candidemia accounted for 10.1% of blood stream
infections compared with 7.9% on the general ward [1].
Luzzati et al. [6] reported a study showing that candide-
mia occurred more frequently in ICUs than on either
surgical or general medical wards. The infection rates
were cited as 15.8/10,000 patient-days in ICUs versus
0.15/10,000 on medical wards and 0.69/10,000 patient-
days on surgical wards. Bougnoux et al. [7] observed a
mean incidence of candidemia of 6.7/1,000 admissions in
ICU patients in France, and candidemia occurred more
frequently in non-neutropenic patients than in patients
with neutropenia [1, 7]. Invasive candidiasis and candi-
demia are associated with increased ICU and hospital stay
of 12.7 and 15.5 days, respectively, and increased total
costs [8–10].
Overall, ICU candidiasis represent one-third of all
invasive candidiasis and is associated with a high mor-
tality rate [11]. A recent study carried out in an adult ICU
in France showed a 61.8% crude mortality [7]. A perhaps
more clinically relevant parameter is the attributable
mortality. This parameter estimates the excess of mor-
tality attributable to the fungal infection compared with
the mortality rate in patients matched for underlying
disease and other risk factors. Thus, attributable mortality
may estimate how mortality may be decreased by effec-
tive antifungal therapy. Attributable mortality of
candidiasis was evaluated retrospectively between 1997
and 2001 in 108 matched pairs [12], the crude mortality
among case patients was 61% compared with 12% in
controls; the resulting ‘‘attributable mortality’’ was
therefore estimated to be 49%. A study performed in the
US evaluating candidemia associated with septic shock
and multiple organ failure showed that, although rela-
tively infrequent in the non-immunocompromized patient,
it was associated with a very high mortality rate [13].
Although not statistically significant, the mortality rate at
28 days in this study was 60% in candidemic septic shock
patients, compared with 46% in bacteremic septic shock
patients. Falagas et al. [14] also assessed the impact of
candidemia on hospital mortality in a systematic review
of seven matched cohort and case–control studies. The
mortality attributed to candidemia, in the reviewed stud-
ies, ranged from 5 to 71%, and for six, the difference in
mortality between cases and controls was statistically
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significant. The authors concluded that despite the meth-
odological heterogeneity, these data suggest that
candidemia is associated with considerable mortality. In
another study recently published, Tumbarello et al. [15]
retrospectively studied the risk factors for mortality of
patients with candidemia. The multivariate analysis
identified three factors associated with mortality: inade-
quate antifungal therapy, infection with biofilm-forming
Candida species, and Apache III score.
The increasing incidence of non-albicans Candida
species could be important, as a prospective study in a
medical–surgical ICU suggested that candidemia due to
non-albicans species was associated with higher mortality
[16]. Blot et al. [17] compared critically ill patients with
fungemia due to C. albicans and C. glabrata. They found
that patients infected by C. glabrata were significantly
older and showed a trend toward a higher mortality. In
cancer patients, Viscoli et al. [18] also suggested that C.
glabrata was associated with a higher mortality rate.
Comparing fluconazole-susceptible with resistant strains in
161 patients, Kovacicova et al. [19] found a significantly
higher attributable mortality in patients infected with a
fluconazole-resistant strain. On the contrary, crude mor-
tality was not different between patients infected by C.
glabrata or C. albicans (respectively 41 vs. 44%, P = 0.7)
in a recent case control study [20], suggesting that uncer-
tainty exists around the relative mortality of different
Candida species, requiring well-controlled studies.
Despite the overwhelming evidence identifying the
increasing mortality and morbidity burden of invasive
candidiasis and candidemia, and its adverse impact on
morbidity and mortality of critically-ill patients, the
optimal management, even in the high-risk ICU patient, is
still debated in the medical literature.
The aim of this article is to summarize the current
management of invasive candidiasis and candidemia in
adult non-neutropenic ICU patients based on a review of
the international literature.
Candida spp. epidemiology in the intensive care unit
Only a limited number of studies have specifically
focused on Candida spp. encountered in the ICU. In one
study carried out over a 4-year period, Aliyu et al. [21]
investigated 92 episodes in 90 patients, C. albicans was
the most-frequently isolated fungal species, C. glabrata
was second. All isolated Candida spp. were susceptible to
amphotericin B, and only 87% were susceptible to
fluconazole.
A larger study conducted over a 5-year period in Italy
recorded 182 episodes of ICU candidemia, with an
average incidence of 2.22 episodes/10,000 patient-days/
year [22]. The authors observed an increased incidence of
candidemia over the years: overall, 40% of cases were
due to C. albicans followed by C. parapsilosis (23%), C.
glabrata (15%), C. tropicalis (9%), and other species
(13%). The results of this study reflected a shift toward an
increased rate of infection with non-albicans Candida
species. This observation correlated with the increasing
use of azoles for prophylaxis or empirical treatment,
which will be discussed later in this review although this
finding has not been corroborated by Shorr et al. in a
recently published study [23]. The influence of azole
prophylaxis on Candida epidemiology has not been
clearly elucidated yet.
A hospital-based study conducted in England and Wales
reported 18.7 episodes of candidemia/100,000 finished
consultant episodes, 45.4% of which occurred in the ICU.
C. albicans was isolated in 64.7% of confirmed cases [24].
In a large European study, Tortorano et al. [25]
showed that Candida albicans was responsible for more
than half of the cases in all patient populations. Candida
glabrata was the most frequent non-albicans isolate in
surgical (16%) patients. These authors concluded that
there was a limited role of species with decreased sus-
ceptibility to azoles in causing bloodstream infections and
a low proportion of antifungal resistance.
In a study from Turkey, 302 isolates from 270 ICU
patients were collected from various samples; C. albicans
was the most frequent species detected (65.6%) followed
by C. parapsilosis (11.3%) and C. glabrata (8.8%) [26].
Of all the isolates, 92.9% were susceptible to fluconazole.
In Canada, 409 Candida isolates were recovered during a
1-day point-prevalence study in 35 ICUs [27]. C. albicans
accounted for 72% of the isolated species, followed by C.
glabrata (16%). Only 4% of the isolates were resistant to
fluconazole and/or itraconazole.
Diagnosis of invasive candidiasis and candidemia
The diagnosis of candidiasis is still a major challenge in
the ICU, and it is often made late in the course of the
infection. This can be explained by several factors: clin-
ical manifestations are non-specific, blood cultures are
usually not positive until late in the course of infection,
and, in approximately 50% of patients, blood culture
sample size may be inadequate, i.e., not performed
according to guidelines with a sample size C20 mL of
blood [28, 29]. Finally, serological tests and cultures,
apart from blood cultures, are non-specific and their
diagnostic accuracy is still debated [29–31]; as a result,
clinicians often disregard a potential diagnosis of candi-
diasis. An additional diagnostic hurdle relates to the fact
that ICU patients may have received prophylactic doses of
fluconazole (e.g., 100 mg) which may render samples
negative at the time of testing.
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A diagnosis usually requires clinical, microbiological,
and biochemical evidence of infection, which even if
positive may not be sufficient or specific enough to guide
optimal treatment. One of the main features in diagnosis
is the evaluation of risk factors for infection. Possible risk
factors have been evaluated in several studies and used to
identify patients in need of pre-emptive or empiric treat-
ment [32, 33]. The optimal timing of these therapeutic
options has still not been completely elucidated. Most
frequently this latter objective was achieved by calculat-
ing a clinical risk score derived from identification of pre-
determined risk factors in patients suspected of having a
fungal infection. It is appropriate to describe these risk
factors first before commenting on clinically relevant risk
scores. The specific role of colonization will then be
discussed before assessing the relevance of biological
tests.
Assessment of risk factors
Commonly recognized risk factors for invasive Candida
infection are listed in Table 1 [2, 34, 35]. Several authors
have used multivariate analyses in an attempt to assess
independent risk factors associated with invasive candidi-
asis [28, 32, 33]. Using a case control study, Wey et al. [36]
identified four factors associated with high risk of candi-
diasis: number of antibiotics received prior to infection
(odds ratio (OR), 1.73 per unit increase); isolation of
Candida spp. from sites other than blood (OR, 10.37);
previous hemodialysis (OR, 18.13), and prior use of a
Hickman catheter (OR, 7.23). Possible risk factors must be
analyzed with extreme caution as they also depend on the
study population: in one study, surgical ICU (SICU)
patients with severe acute pancreatitis who did develop
invasive candidiasis could not be differentiated from those
who did not become infected when evaluated according to
classical parameters such as Apache II score or previous
antibiotic treatment [37]. In another study focusing on
Candida peritonitis in a SICU, four variables could be
identified: the Apache II score, respiratory failure on
admission, upper gastrointestinal tract site peritonitis, and
positive results for Candida following direct testing of
peritoneal fluid [38]. These observations were confirmed in
a recent study in 59 consecutive multidisciplinary ICU
patients where both high colonization index and recent
extensive gastro-abdominal surgery were correlated with
invasive candidiasis and candidemia [39]. Other risk fac-
tors have also been identified, such as the presence of a
central venous catheter [21] or hemodialysis [40]. In a
multicenter study on risk factors in surgical patients, the
incidence of fungal infections increased from 0.98/1,000 to
1.42/1,000 SICU days when a central venous catheter was
in place [34]. Another major factor associated with an
increased risk of invasive candidemia is the length of stay in
the ICU; in a small study, Pelz et al. [41] showed a clear
increase in risk beyond the seventh day of stay.
Prediction rules
In an attempt to improve this risk factor driven approach,
several authors have tried to develop models to identify
independent factors that are predictive of invasive candi-
diasis, and use these factors to build clinically relevant
scores that may help clinicians to identify, implement and
adapt an optimal therapeutic approach. In a two-stage
study, Michalopoulos et al. [42] identified independent
predictive factors and prospectively validated them in two
centers. Independent predictors were ongoing invasive
mechanical ventilation C10 days, hospital-acquired bac-
terial infection and/or bacterium, cardiopulmonary bypass
duration[120 min, and diabetes mellitus. Of these, the first
two factors were the strongest predictors. This study needs,
however, to be analyzed cautiously because it only
involved 19 patients with candidemia. In another study,
Leon et al. [28] described a clinical score based on four
parameters derived from a logit model: surgery, multifocal
colonization, total parenteral nutrition, and severe sepsis. A
cut-off value of 2.5 was associated with a sensitivity of 81%
and a specificity of 74%. Using a less formal approach,
Ostrosky-Zeichner et al. attempted to identify patients at
high risk for invasive candidiasis in the ICU. The best-
performing rule was C1 day of systemic antibiotic therapy
or presence of a central venous catheter, and at least two of
the following: total parenteral nutrition, any form of dial-
ysis, any major surgery, pancreatitis, any use of steroids, or
use of an immunosuppressive agent [33].
Clinical diagnostic criteria
Of all the risk factors discussed in the previous section,
Candida colonization should be highlighted. Invasive
Candida infections represent a growing challenge in the
ICU and as a consequence treatment of high-risk patients
is more frequently initiated pre-emptively or empirically.
Table 1 Commonly recognized risk factors for invasive Candida




Colonization with Candida spp.
Broad-spectrum antibiotic use
Presence of a central venous catheter
Hemodialysis or renal failure






One of the main concerns in the ICU, therefore, is how to
identify these patients and propose appropriate treatment
algorithms, with the presumption that, in most cases, the
risk of invasive candidiasis and candidemia is related to
the density and extent of fungal colonization over time.
One of the most important questions, which if answered
positively would support the rationale for prophylaxis, is
whether colonizing species portend subsequent fungal
infection. An earlier study by Petri et al. [43] showed that
64% of ICU patients were colonized, and that all infected
patients had been previously colonized. A related ques-
tion as yet unanswered is whether colonization of certain
sites carries more predictive impact versus other coloni-
zation sites.
Fungal burden was also found to be an independent
risk factor in a multivariate analysis carried out on pre-
dictors of fungal infections found in ICU patients [41].
More recent studies using microsatellite markers have
confirmed that, in most cases, the fungal acquisition was
mainly endogenous [44, 45].
In a pioneer study, Pittet et al. [46] proposed a clinical
colonization index to assess fungal colonization in high-
risk SICU patients. In this 6-month prospective cohort
study, the investigators evaluated 29 patients. Of these, 11
(38%) developed severe infections (8 candidemia); the
others were heavily colonized but did not require specific
therapy. The results of this study identified two inde-
pendent factors that predicted subsequent invasive
Candida infection: the severity of illness as assessed by
the Apache II score, and the intensity of Candida spp.
colonization defined as the colonization index (CI). In this
study the colonization index was defined as the number of
distinct non-blood body sites (dbs) colonized by Candida
spp. over the total number of distinct sites tested per
patient. The results of this study led the authors to con-
clude that systematic screening of critically ill patients
with risk factors had the potential to identify those
requiring so-called pre-emptive therapy with the threshold
for intervention set at a CI of 0.5. The authors developed a
corrected index (product of the CI times the ratio of the
number of dbs showing heavy growth to the total of dbs
growing Candida spp.) which was associated with a 100%
sensitivity and specificity.
Laboratory diagnosis of invasive candidiasis
and candidemia
As mentioned previously, diagnosis of invasive candidi-
asis and candidemia remains a great challenge, since
symptoms and signs are usually non-specific, microbio-
logical cultures are difficult to analyze, and histological
specimens require invasive procedures [29, 30, 46].
A positive blood culture or the isolation of Candida
spp. from a normally sterile site (except urine) provides
test results that are easy to analyze, but all too often this
level of positive evidence is not available to the clinician.
Several techniques have recently been proposed to assist
the clinician and improve the diagnostic accuracy.
Surrogate markers
(1 ? 3)-b-D-glucan. (1 ? 3)-b-D-glucan is a compo-
nent of the cell wall of many fungi and has been proposed
as a non-specific marker for invasive fungal infections.
Using commercially available assays (colorimetric or
kinetic), this method was evaluated to add another ele-
ment to the diagnostic panel for invasive candidiasis.
Sensitivity and specificity have been estimated to be 69.9
and 87.1%, respectively [47], as there are a high number
of false positive results. Furthermore the specificity of the
test is hampered by ß-glucan contamination of certain
antibiotics and materials, such as surgical gauzes,
requiring further validation of the assay in the appropriate
ICU setting before routine use can be recommended.
Mannans and other markers. Like glucans, mannans are
major components of the C. albicans cell wall, but in
contrast to glucans, mannans are non-covalently bound at
the cell surface and are highly immunogenic [48]. The use
of mannan antigenemia has been suggested to facilitate the
diagnosis of invasive candidiasis; the most important lim-
itation was rapid clearance of the antigen from the patient’s
sera [49]. To improve test performance, Sendid et al. sug-
gested combining antigen and antibody detection. This
possibility was explored using 162 serum samples selected
from 63 patients with clinically proven candidiasis, com-
pared with 98 control samples [50]. Combined analysis
showed a sensitivity and specificity of 80 and 93%,
respectively, suggesting a potential value in clinical prac-
tice. This test was also effective with non-albicans Candida
species [51]. A second test based on the detection of beta-
linked oligomannoses was subsequently developed and
associated with the analysis of alpha-linked oligomannos-
es. The results showed a slight improvement in specificity
to 95%, with a sensitivity of 90% [52]. The routine use of
these tests could be valuable to increase early diagnosis, but
does not, by itself, offer a definitive solution for diagnosis.
Other tests have also been evaluated. A C. albicans
germ tube antibody (CAGTA) detection test was evalu-
ated and compared to a standard test in a retrospective
study [53]. Using 172 sera from 51 hematological and
intensive care patients, Candida albicans IFA IgG test
showed a sensitivity of 84.4% and a specificity of 94.7%,
while the standard test showed a sensitivity of 78.1% and
a specificity of 100%. Several other antigens expressed on
the C. albicans cell wall have been recently identified.
Specific antibodies directed toward the hyphal wall pro-
tein 1 (Hwp1) were developed and compared with CAGT
antibodies [54]. Detection of these antigens needs addi-
tional clinical confirmation.
59
Polymerase chain reaction. The amplification of geno-
mic sequences through polymerase chain reaction (PCR)
testing has mostly been developed for invasive aspergil-
losis but is not routinely used in invasive candidiasis. A
recent Japanese publication describes a novel PCR assay
directed to five common Candida spp. [55]. A recent
study evaluated prospectively, in non neutropenic ICU
patients, three TaqMan-based polymerase chain reaction
assays and the results showed a 90.9% sensitivity, and
100% specificity suggesting a potential usefulness of this
method [56]. These results need further evaluation.
Conclusion
ICU patients have many risk factors for developing
invasive candidiasis or candidemia. For the specialist, the
management of invasive candidiasis and candidemia,
from diagnosis to selection of the therapeutic protocol, is
often a challenge. Apart from cases with positive blood
cultures or fluid/tissue biopsy, diagnosis is neither sensi-
tive nor specific. It relies on many different factors
including clinical and laboratory findings, but there is
clearly a need for more specific diagnostic markers.
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